MegaNatural-BP claims supported
This article was originally published in The Tan Sheet
Executive SummaryConstellation Wines U.S./PolyPhenolics supports certain claims for its MegaNatural-BP dietary supplement, but should "clearly and conspicuously" communicate the supplement could be used as a part of a lifestyle management program by those with prehypertension and metabolic syndrome, the National Advertising Division states in an Oct. 14 decision. The advertiser submitted two clinical trials, which NAD says provide a reasonable basis for claims such as: "In the second study on participants with prehypertension, their systolic blood pressure dropped 8 mm and diastolic dropped 5 mm when taking 300 mg once per day for 2 months." The Council for Better Business Bureaus group recommends discontinuing the claim, "Provide relief with half the cost, half the dose and half the time," but says the advertiser can discuss the differences between MegaNatural-BP and antigen-converting enzyme inhibitors
You may also be interested in...
Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.
As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.
A trio of legislative proposals to lower high-cost “surprise” medical bills that limit what physicians and hospitals, labs, and imaging facilities can charge patients, emerged this winter from three different US congressional committees with health care jurisdiction. Check out our detailed chart that sorts out some of the provisions of the bills of interest to device and diagnostics firms.